Clinical trials: RhA - Rheumatoid Arthritis
Rheumatoid Arthritis
Enbrel Liquid Immunogenicity Protocol
The purpose of this study is to assess the antibody formation to Enbrel liquid in subjects with Rheumatoid Arthritis
- Trial name
- NCT00249041
- Testing
- 50 mg Etanercept, Enbrel liquid
- Volunteers
- 447 people
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
The study is being conducted to evaluate the absorption, metabolism and excretion of [14C]SHR0302 in healthy Chinese adult male subjects.
- Trial name
- NCT05047341
- Testing
- SHR0302、[14C]SHR0302
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
The purpose of this study is to evaluate biosimilarity between test product MabionCD20® and the reference product - MabThera® (rituximab) and to demonstrate comparative safety and tolerability of a single course of treatment of…
- Trial name
- NCT02468791
- Testing
- Rituximab
- Where
- 51 sites in Bosnia and Herzegovina, Georgia and 3 more
- Volunteers
- 709 people
- Sponsor
- Mabion SA
Rheumatoid Arthritis
An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis
This open-label, single arm, multicenter long-term extension study of WA19926 evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who completed the…
- Trial name
- NCT01664598
- Testing
- Tocilizumab
- Where
- 12 sites in Russia
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
This is an open-label, randomized, crossover Phase 1 study to evaluate the bioequivalence, pharmacokinetics, and safety of two oral SKI-O-703 drugs (test and reference) in healthy adults under fed conditions.
- Conditions
- Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP), Rheumatoid Arthritis (RA)
- Trial name
- NCT07675226
- Testing
- SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Oscotec Inc.
Rheumatoid Arthritis
Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis
This is a phase 2a study to be run in 2-3 countries in European Union involving 5-6 sites. It will enroll approximately 80 patients to ensure 40 randomized with active rheumatoid arthritis.
- Trial name
- NCT03368235
- Testing
- AZD9567, Prednisolone
- Where
- 5 sites in Netherlands, Sweden
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Arthritis, Rheumatoid
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
RA is a chronic, systemic inflammatory autoimmune disease which requires treatment for a long time period, hence it is important to study the long-term safety and efficacy of the continuous treatment with GSK3196165 over several…
- Trial name
- contRAst X (NCT04333147)
- Testing
- Otilimab (GSK3196165), csDMARD(s)
- Where
- 375 sites in United States, Argentina and 25 more
- Volunteers
- 2,916 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis
This study is to investigate and describe the treatment patterns and effect of tofacitinib indicators for patients with Rheumatoid Arthritis (RA) assessing real world patient data entered in the Corrona RA Registry on or after…
- Trial name
- NCT04721808
- Where
- United States
- Volunteers
- 1,712 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
This 2 arm study will assess the safety and efficacy of tocilizumab monotherapy versus methotrexate in patients with active rheumatoid arthritis (RA).
- Trial name
- NCT00109408
- Testing
- Methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 147 sites in United States, Argentina and 16 more
- Volunteers
- 673 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
This is a double-blind, randomized, placebo- and active-controlled study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) doses of LFD-200.
- Trial name
- NCT07207954
- Testing
- LFD-200, Oral Prednisone
- Where
- 10 sites in Australia, Georgia and 3 more
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Lifordi Immunotherapeutics, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
- Trial name
- NCT07729995
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Luminary Therapeutics
Rheumatoid Arthritis
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.
- Trial name
- NCT03233230
- Testing
- M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID
- Where
- 97 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)
This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core…
- Trial name
- NCT01662063
- Testing
- Tocilizumab
- Where
- 79 sites in United States, Puerto Rico
- Volunteers
- 218 people
- Sponsor
- Genentech, Inc.
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Rheumatoid Arthritis
Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
The purpose of the study is to assess the long-term safety and tolerability of repeated administration of adalimumab in Japanese subjects with rheumatoid arthritis.
- Trial name
- NCT00235872
- Testing
- adalimumab
- Where
- 25 sites in Japan
- Volunteers
- 309 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab).
- Trial name
- REFLECTIONS (NCT01526057)
- Testing
- PF-05280586, MabThera, Rituxan
- Where
- 84 sites in United States, Australia and 8 more
- Volunteers
- 220 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis
This open-label, single arm, multicenter long-term extension study will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who have completed the…
- Trial name
- NCT01655381
- Testing
- Tocilizumab
- Where
- 6 sites in France
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Osteo Arthritis Knee, Rheumatoid Arthritis
ROSA Knee Intraoperative Planning Flexibility Study
The purpose of this study is to verify that an orthopedic surgical assist robot (ROSA Knee System) can provide intraoperative adjustment of osteotomy angle and volume for total knee arthroplasty (TKA) based on feedbacks obtained…
- Trial name
- IntraOP (NCT05966519)
- Testing
- Total Knee Replacement (TKR)
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Zimmer Biomet
Rheumatoid Arthritis
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
A randomized, double-blind, double-dummy, positive-controlled, phase 3 study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subjects who had an inadequate response or intolerance to Biologic DMARDs.
- Trial name
- TARA (NCT06020144)
- Testing
- TLL-018, Tofacitinib
- Where
- China
- Volunteers
- 459 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.